Search Technologies

The National Cancer Institute (NCI) seeks licensees for a novel computer program that converts existing CT scan output into organ radiation doses.

The National Cancer Institute (NCI) seeks licensees and/or collaborators for a T-cell receptor (TCR) that specifically targets CD22 in the context of Human Leukocyte Antigen (HLA)-A*02:01 in B-lymphoid malignancies such as non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. The TCR is being developed as a cellular immunotherapy for the treatment of lymphomas and leukemias.

The National Cancer Institute (NCI) seeks research co-development partners for a companion diagnostic (CDx) that detects human leukocyte antigen (HLA) loss-of-heterozygosity (LOH) and other biomarkers to predict efficacy of TCR-T cell adoptive transfer, immune checkpoint inhibition (ICI), tumor infiltrating lymphocytes (TIL), and other TCR-mediated immunotherapies.

National Cancer Institute (NCI) seeks licensees or co-development research collaborations for a novel method of generating microtissue spheroids that allows for creation of a self-contained spheroid integrating both cells and decellularized tissue ECM dense regions rather than cell-only spheroids.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development seeks research co-development partners and/or licensees to further develop and commercialize its methods of noninvasively and directly determining the absolute homeostatic state, metabolic activity, function, and viability of isolated cells, or tissues (ex vivo or in vivo), such as the Central Nervous System (CNS). The method uses Nuclear Magnetic Resonance or Magnetic Resonance Imaging measurements of the rate at which endogenous water exchanges across cell membranes.

Chimeric antigen receptor (CAR) T cells that specifically target Glypican 2 (GPC2) are strong therapeutic candidates for patients with neuroblastoma and other GPC2-expressing cancers. The inventors at the National Cancer Institute (NCI) have developed a potent anti-GPC2 (CT3) CAR containing CD28 hinge and transmembrane domains (CT3.28H.BBζ) that is available for licensing and co-development.

Scientists at National Cancer Institute (NCI) Center for Cancer Research (CCR) identified selective tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors that may be used in combination with topoisomerase 1 (TOP1) inhibitors for synergistic treatment of solid tumors. NCI seeks research co-development partners and/or licensees for commercializing the TDP1 inhibitors as part of an anti-cancer therapy.

The NCI seeks parties interested in research co-development and/or licensing of TCRs targeting the BRAF V600E mutation. These TCRs are HLA-A*0301 restricted. The BRAF V600E mutation is common among cancer patients, giving the TCRs broad therapeutic potential in immunotherapy against multiple cancers.

The National Cancer Institute (NCI) seeks licensees for an automated digital pathology device which integrates tissue sectioning, staining, and image acquisition. The device is compatible with high-throughput data analyses.